Trial Profile

Tolerability and CK-1827452 Plasma Concentrations During Intravenous and Immediate-Release Oral CK-1827452 In Patients With Ischemic Cardiomyopathy and Angina.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Omecamtiv mecarbil (Primary) ; Omecamtiv mecarbil (Primary)
Indications Angina pectoris; Cardiomyopathies; Heart failure
Focus Therapeutic Use
Sponsors Cytokinetics

Most Recent Events

15 Sep 2009 Results were presented at the 2009 Heart Failure Society of America Annual Meeting in Boston, Massachusetts, according to a Cytokinetics media release.
31 Aug 2009 Results presented at ESC Congress 2009: Annual Congress of the European Society of Cardiology.
31 Aug 2009 Results were presented at the European Society of Cardiology Congress 2009, according to a Cytokinetics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com